Although anaphylactoid reactions to muscle-relaxant drugs are now well recognised, there has been no general agreement on the mechanism(s) underlying the responses. By covalently coupling alcuronium and tubocurarine to a solid phase carrier and using the resultant complexes in radioimmunoassay experiments with patients' sera and 125I-anti-human Ig£, we have found high levels of drug-specific Ig£ antibodies in the sera of some subjects who reacted to these muscle relaxants. These results provide important supporting evidence that, in some patients at least, lifethreatening anaphylactoid reactions to muscle-relaxant drugs are mediated by drug-specific Ig£ antibodies.
support and by using the drug-carrier complexes in radioimmunoassays with patients' sera and 1251-labelled anti-human IgE.
MATERIALS AND METHODS

Subjects and Sera
Sera were taken from 24 patients one month after lifethreatening (severity grade 3)9 anaphylactoid reactions to alcuronium or d-tubocurarine. Diagnosis of the drug sensitivities was confirmed by positive intradermal tests to the muscle relaxants.~ Twenty-two patients reacted to aIcuronium and two patients to d-tubocurarine. Three patients in the former group also had a documented previous reaction to d-tubocurarine. Sera from healthy adults were collected from volunteers. Cord serum was provided by the Department of Obstetrics, Royal North Shore Hospital. All sera were stored at -20°C.
Preparation of drug-solid phase complexes
A. Alcuronium Alcuronium dichloride (Roche) (60 mg) was reacted with Epoxy-activated Sepharose 1o (Pharmacia) by adjusting the pH to 12 with 2.5 M sodium hydroxide and shaking the mixture for 20 hours at 30°C. The beads were then washed successively with water, 0.1 M borate buffer pH 8 and 0.1 M acetate buffer pH 4 and then incubated with 1 M ethanolamine pH 9 for 4 hours at room temperature to block free activated sites. Unreacted ethanolamine was removed by washing with the above buffers and then water. The same procedure was used to couple ethanolamine (600 mg) or D-galactosamine (60 mg) to Sepharose (l g).
B. Tubocurarine
Sepharose (1.5 ml of sedimented gel) was activated by treatment with divinylsulphone ll (0.15 ml) in sodium carbonate buffer pH 11 at room temperature for 70 minutes. After washing the gel with distilled water tubocurarine chloride (Well come) 60 mg was added and the pH adjusted to 10.1 with sodium hydroxide. The gel was rotated for 16 hours at room temperature and then washed and blocked as described for alcuronium-Sepharose.
Radioimmunoassay
Serum (50 Ill) was added to the solid phase (alcuronium-, tubocurarine-, ethanolamine-, or D-galactosamine-Sepharose) 6 mg, and left at room temperature for three hours. Tubes were then washed and centrifuged three times with phosphate-buffered saline containing Tween 20 before adding 20,000-40,000 cpm of 125I-antihuman IgE (Pharmacia). After standing overnight, tubes were washed three times and counted in a Packard Auto Gamma Spectrometer.
RESULTS Sera from 13 of the 24 patients clearly showed the presence of drug-specific IgE antibodies reacting with alcuronium, d-tubocurarine or both drugs. This was demonstrated by the uptake of 125I-Iabelled anti-IgE. Four sera, Bu, Ch, Cu and Po were considered to be borderline positives for alcuronium while Sh and Wau were considered borderline for tubocurarine. The radioactive Anaesthesia and inlellsive Care, Vol. J i, No. 3, August, 1983 uptakes were compared with those obtained with cord serum (IgE free control) and with sera from normal, healthy subjects ( Table 1) .
The radioactive uptakes were usually less than 10J0 and never greater than 2.6070 for patient or control sera when specificities were checked with ethanolamine-and D-galactosamine-Sepharose complexes, Se ph arose alone and empty plastic tubes instead of drug complexes.
Six patients, Be, Bu, Ch, Hu, Po and Wh, had clear-cut or borderline uptake levels with one drug only while 9 patients showed clear or borderline uptakes with both drugs ( Table 1) .
DISCUSSION
Using the radioimmunoassay described here we have shown that IgE antibodies to musclerelaxant drugs do occur and that it is now possible to quantitatively measure these antibodies for alcuronium and d-tubocurarine. From these direct binding studies and experience gained in the use of Pharmacia 125I-anti-human IgE in the radioallergosorbent test (RAST),12,13 we concluded that alcuroniumreactive IgE antibodies are certaintly present in the sera of 10, and probably in the sera of 4 other patients, and tubocurarine-reactive antibodies were present in the sera of 9 patients and probably in the sera of 2 others. RAST uptakes that are at least two and a half to three times control levels (that is, cord serum uptakes), are generally regarded as positive.1 2 .1 4 We took a radioactive uptake of greater than three times the cord figure as positive and an uptake of 2.5-3 times the cord value as a borderline positive. Hence, for alcuronium, sera from subjects Bu, Ch, Cu and Po, and for tubocurarine, sera from subjects Sh and Wau were regarded as borderline, but probably positive. Radioimmunoassay results for the remaining 9 subjects investigated were considered negative.
Further study is necessary to determine the factors responsible for the positive results as opposed to the negatives, since the reactions in both groups were similar in terms of the clinical features and their severity ( Table 1) . Possibilities include different mechanisms causing the reactions, or the method not detecting alternative antigenic forms of the drug or drug hapten complex. Some patients' sera reacted with both drugs, suggesting separate sensitisation to each drug or cross-reactivity of the IgE antibodies. Recent findings (Baldo and Fisher, unpublished) indicated that cross-reactions do occur in sensitive patients; IgE antibodies to one muscle relaxant frequently react with another. The common allergenic sites on the different Anaesthesia and Intensive Care, Vol. 1 J, No. 3, August, 1983 molecules appear to be the quaternary ammonium groups which occur in alcuronium and tubocurarine and also in decamethonium, succinylcholine, pancuronium and gallamine. Cross-sensitivity between alcuronium and d-tubocurarine is well recognised clinically. 15 Although the mechanisms for anaphylactoid reactions to muscle-relaxant drugs have remained obscure,4.8 our results support Fisher's conclusion 4 • 5 that a type I, IgEmediated allergic reaction is operative in at least some of the patients and confirm the quantitative indirect detection of IgE antibodies on passive transfer testing. Further work is now planned to investigate more closely the clinical relevance of the alcuronium and tubocurarine reactive IgE antibodies and to assess the value of the radioimmunoassay as a diagnostic aid.
The preparation of carrier complexes of alcuronium and d-tubocurarine and the procedures involved in the radioimmunoassay are straightforward and can readily be used for the detection of muscle-relaxant, drug-specific IgE antibodies in patients before or after anaesthesia. After further evaluation of their sensitivities and specificities the assays may prove valuable to anaesthetists as a diagnostic procedure for the detection of patients with potentially lethal sensitivity to quaternary ammonium muscle relaxants.
